• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • A combination corticosteroid and antihistamine targets key innate immune pathways at the nasal mucosa in allergic rhinitis

    Author(s)
    Smith, PK
    Watts, AM
    Zhang, P
    West, NP
    Cripps, AW
    Cox, AJ
    Griffith University Author(s)
    Cox, Amanda J.
    West, Nic P.
    Cripps, Allan W.
    Smith, Peter K.
    Watts, Annabelle
    Zhang, Ping
    Year published
    2019
    Metadata
    Show full item record
    Abstract
    Background: A novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray has been shown to provide greater symptom relief than treatment with either compound alone in individuals with moderate / severe allergic rhinitis. The aim of this study was to characterise the effect of either intra‐nasal azelastine (Azep), fluticasone propionate (Flixonase) or a combination formula of azelastine hydrochloride and fluticasone propionate in a single spray on mucosal immune gene expression in the nose of individuals with moderate to severe AR. Method: This was a double‐blind, three‐armed parallel group ...
    View more >
    Background: A novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray has been shown to provide greater symptom relief than treatment with either compound alone in individuals with moderate / severe allergic rhinitis. The aim of this study was to characterise the effect of either intra‐nasal azelastine (Azep), fluticasone propionate (Flixonase) or a combination formula of azelastine hydrochloride and fluticasone propionate in a single spray on mucosal immune gene expression in the nose of individuals with moderate to severe AR. Method: This was a double‐blind, three‐armed parallel group study in which 48 individuals (n = 16 per group) with moderate/severe AR and sensitive to dust‐mite only or dust mite and grass allergens completed a 14‐day medication washout followed by a seven‐day treatment period. Participants completed a symptom and medication diary and the mini‐rhinoconjunctivitis quality of life (m‐RQLQ) questionnaire daily. At day 0 (pre‐treatment) and day 7 (end of treatment) participants completed the visual analogue scale (VAS) and provided a nasal lavage and blood sample. Samples were analysed with the PanCancer Immune Profiling kit (Nanostring Technologies, Seattle, USA). Results: All clinical and laboratory baseline parameters were similar in the groups with the exception of a significant difference in eosinophil counts, with the Azep group having a 50% lower eosinophil count than the Flixonase group (P = .04) but not the Dymista group. Participants in the Dymista group had the strongest statistically significant reduction in symptoms and improvement in quality of life (P < .0001). A total of 588 immune genes were expressed above background thresholds in nasal lavage samples across the three groups. Flixonase altered the expression of 148 genes significantly, compared to 56 immune genes in the Dymista group and 23 immune genes in the Azep group. Gene set analysis indicates that Flixonase altered the greatest number of pathways (n = 142 Flixonase; n = 53 for Dymista; n = 37 for Azep). Dymista significantly altered a number of innate immune pathways that were not altered by the monotherapies. Conclusion: The observation that Dymista alters innate immune pathways provides insight into potential mechanisms to explain the clinical effects observed with this combination therapy and provides potential biomarkers to target in other atopic conditions.
    View less >
    Conference Title
    ALLERGY
    Volume
    74
    Issue
    S106
    DOI
    https://doi.org/10.1111/all.13957
    Subject
    Immunology
    Science & Technology
    Life Sciences & Biomedicine
    Allergy
    Publication URI
    http://hdl.handle.net/10072/386961
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander